{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0"},{"groupId":"OG001","value":"0.0"}]}],"title":"Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3"},{"groupId":"OG001","value":"9.4"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.2"},{"groupId":"OG001","value":"73.6"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4"},{"groupId":"OG001","value":"16.0"}]}],"title":"Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.9"}]}],"title":"Grade 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"106"}],"units":"Participants"}],"description":"Maximum grade toxicity that is definitely, probably, or possibly related to protocol treatment.","groups":[{"description":"Loading dose of cetuximab followed by radiation therapy with weekly cisplatin and cetuximab.","id":"OG000","title":"RT+Cisplatin+Cetuximab"},{"description":"Loading dose of cetuximab followed by radiation therapy (RT) with weekly docetaxel and cetuximab.","id":"OG001","title":"RT+Docetaxel+Cetuximab"}],"paramType":"NUMBER","populationDescription":"Eligible patients who started protocol treatment and did not withdraw consent","reportingStatus":"POSTED","timeFrame":"From start of treatment to last follow-up. Analysis occurs at the time of the primary endpoint analysis.","title":"Frequency of Other Acute and Late Toxicity","type":"SECONDARY","unitOfMeasure":"percentage of participants"}